Drug Trial Radar · NCT03997760
A Study of SHP655 (rADAMTS13) in Sickle Cell Disease
Last checked: Nov 19, 2026Latest source record: Apr 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
Oct 21, 2019
Primary completion
Oct 26, 2022
Study completion Oct 26, 2022
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- Collaborators
- Takeda Development Center Americas, Inc.
- First posted
- Jun 25, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TAK-755 (previously known as SHP655) is a medicine used to treat sickle cell disease (SCD). The main aim of the study is to measure the safety and tolerability of TAK-755 in SCD participants. Study participants will receive TAK-755 or placebo on Day 1. Their SCD will be treated by their doctor according to their doctor's usual clinical practice. During the study, participants will be asked to follow-up on 13 days following SHP655 or placebo administration for safety assessment. Maximum duration of participation is expected to be about 2 months.
Conditions
- Sickle Cell Disease
Interventions
TAK-755Drug
Participants will receive TAK-755 as a single IV infusion at one of the 3 dose levels of 40 IU/kg, 80 IU/kg, or 160 IU/kg.
PlaceboOther
Participants will receive placebo matched to TAK-755 of the 3 dose levels of 40 IU/kg, 80 IU/kg, and 160 IU/kg as single IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious (TEAEs)Time frame: From date of signing informed consent up to end of study visit (Day 28)
- Number of Participants Who Developed Positive Binding Anti-ADAMTS13 and Inhibitory Anti-ADAMTS13 Antibodies to TAK-755Time frame: From date of signing informed consent up to end of study visit (Day 28)
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Arkansas Children's Hospital
Little Rock, Arkansas
University of Colorado Sickle Cell Treatment and Research Center
Aurora, Colorado
Sickle Cell Center
Denver, Colorado
University of Illinois
Chicago, Illinois
Ochsner Health System
New Orleans, Louisiana
Johns Hopkins University School Of Medicine
Baltimore, Maryland
Levine Cancer Institute
Charlotte, North Carolina
Duke University Medical Center
Durham, North Carolina
East Carolina University
Greenville, North Carolina
Ohio State University Medical Center
Columbus, Ohio
Medical University of South Carolina (MUSC)
Charleston, South Carolina
University of Tennessee -- Memphis
Memphis, Tennessee
VCU Health - Research Parent
Richmond, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.